Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly

By De Donato S.   Granoff D.   Minutello M.   Lecchi G.   Faccini M.   Agnello M.   Senatore F.   Verweij P.   Fritzell B.   Podda A.  

Vaccine, Vol. 17, Iss. 23, 1999-08 ,pp. : 3094-3101

Elsevier

Access to resources Recommend Favorite

Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons

By Minutello M.   Senatore F.   Cecchinelli G.   Bianchi M.   Andreani T.   Podda A.   Crovari P.  

Vaccine, Vol. 17, Iss. 2, 1999-01 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59-adjuvanted influenza vaccine or a conventional non-adjuvanted subunit vaccine during highly active antiretroviral therapy

By Iorio A.M.   Francisci D.   Camilloni B.   Stagni G.   De Martino M.   Toneatto D.   Bugarini R.   Neri M.   Podda A.  

Vaccine, Vol. 21, Iss. 25, 2003-09 ,pp. : 3629-3637

Elsevier

Access to resources Recommend Favorite

Comparison of the reactogenicity and immunogenicity of a two injection combined high-dose hepatitis A and hepatitis B vaccine to those of Twinrix&unknown;

By Greub G.   Genton B.   Safary A.   Thoelen S.   Frei P.C.  

Vaccine, Vol. 19, Iss. 9, 2000-12 ,pp. : 1113-1117

Elsevier

Access to resources Recommend Favorite

Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9-11, 12-14 or 15-17 months of age *

By Klinge  

Vaccine, Vol. 18, Iss. 27, 2000-07 ,pp. : 3134-3140

Elsevier

Access to resources Recommend Favorite